1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends

Envision Healthcare Corporation - Strategy and SWOT Report

  • January 2016
  • 26 pages
  • MarketLine
Report ID: 3695768

Summary

Table of Contents

Search Inside

Introduction

Envision Healthcare Corporation - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Envision Healthcare Corporation required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Envision Healthcare Corporation in the form of a SWOT analysis

- An in-depth view of the business model of Envision Healthcare Corporation including a breakdown and examination of key business segments

- Intelligence on Envision Healthcare Corporation’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Envision Healthcare Corporation, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Envision Healthcare Corporation (Envision Healthcare or 'the company'), formerly known as Emergency Medical Services Corporation, is a provider of healthcare-related services to consumers, hospitals, healthcare systems, health plans and local, state and national government entities in the US. The company operates in the US, where it is headquartered in Greenwood Village, Colorado. The company had 14,664 employees (including 6,849 part-time employees) as on December 31, 2014. The company recorded revenues of $4,397.6 million during the financial year ended December 2014 (FY2014), an increase of 18% over FY2013. The operating profit of the company was $388.5 million in FY2014, an increase of 40.4% over FY2013. The net profit of the company was $125.5 million in FY2014, as compared to a net profit of $6 million in FY2013.

Reasons to Purchase:

- Gain understanding of Envision Healthcare Corporation and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Envision Healthcare Corporation as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Envision Healthcare Corporation’s business structure, strategy and prospects

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017

  • $ 3500
  • Company report
  • June 2017
  • by Global Markets Direct

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017 Summary According to the recently published report 'Integrin Beta ...

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2017

  • $ 3500
  • Company report
  • July 2017
  • by Global Markets Direct

Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2017 ...

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H2 2017

  • $ 3500
  • Company report
  • July 2017
  • by Global Markets Direct

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H2 2017 Summary Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.